Literature DB >> 22033174

Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment.

Shahrokh F Shariat1, Behfar Ehdaie, Michael Rink, Eugene K Cha, Robert S Svatek, Thomas F Chromecki, Harun Fajkovic, Giacomo Novara, Scott G David, Siamak Daneshmand, Yves Fradet, Yair Lotan, Arthur I Sagalowsky, Thomas Clozel, Patrick J Bastian, Wassim Kassouf, Hans-Martin Fritsche, Maximilian Burger, Jonathan I Izawa, Derya Tilki, Firas Abdollah, Felix K Chun, Guru Sonpavde, Pierre I Karakiewicz, Douglas S Scherr, Mithat Gonen.   

Abstract

BACKGROUND: Radical cystectomy (RC) with pelvic lymph node dissection (LND) is the standard of care for refractory non-muscle-invasive and muscle-invasive bladder cancer. Although consensus exists on the need for LND, its extent is still debated.
OBJECTIVE: To develop a model that allows preoperative determination of the minimum number of lymph nodes (LNs) needed to be removed at RC to ensure true nodal status. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from 4335 patients treated with RC and pelvic LND without neoadjuvant chemotherapy at 12 academic centers located in the United States, Canada, and Europe. MEASUREMENTS: We estimated the sensitivity of pathologic nodal staging using a beta-binomial model and developed clinical (preoperative) nodal staging scores (cNSS), which represent the probability that a patient has LN metastasis as a function of the number of examined nodes. RESULTS AND LIMITATIONS: The probability of missing a positive LN decreased with an increasing number of nodes examined (52% if 3 nodes were examined, 40% if 5 were examined, and 26% if 10 were examined). A cNSS of 90% was achieved by examining 6 nodes for clinical Ta-Tis tumors, 9 nodes for cT1 tumors, and 25 nodes for cT2 tumors. In contrast, examination of 25 nodes provided only 77% cNSS for cT3-T4 tumors. The study is limited due to its retrospective design, its multicenter nature, and a lack of preoperative staging parameters.
CONCLUSIONS: Every patient treated with RC for bladder cancer needs an LND to ensure accurate nodal staging. The minimum number of examined LNs for adequate staging depends preoperatively on the clinical T stage. Predictive tools can give a preoperative estimation of the likelihood of nodal metastasis and thereby allow tailored decision-making regarding the extent of LND at RC.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22033174     DOI: 10.1016/j.eururo.2011.10.011

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  27 in total

Review 1.  The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder.

Authors:  Romain Mathieu; Ilaria Lucca; Morgan Rouprêt; Alberto Briganti; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2016-07-19       Impact factor: 14.432

Review 2.  The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?

Authors:  Karim Bensalah; Morgan Roupret; Evanguelos Xylinas; Shahrokh Shariat
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

Review 3.  Lymph node dissection in bladder cancer: Where do we stand?

Authors:  Cory M Hugen; Siamak Daneshmand
Journal:  World J Urol       Date:  2015-12-28       Impact factor: 4.226

Review 4.  Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent.

Authors:  Lars Weisbach; Roland Dahlem; Giuseppe Simone; Jens Hansen; Armin Soave; Oliver Engel; Felix K Chun; Shahrokh F Shariat; Margit Fisch; Michael Rink
Journal:  Int Urol Nephrol       Date:  2013-07-25       Impact factor: 2.370

5.  External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study.

Authors:  Evanguelos Xylinas; Luis Kluth; Malte Rieken; Morgan Rouprêt; Bashir Al Hussein Al Awamlh; Thomas Clozel; Maxine Sun; Pierre I Karakiewicz; Mithat Gonen; Shahrokh F Shariat
Journal:  Urol Oncol       Date:  2016-11-03       Impact factor: 3.498

6.  [Functional imaging in bladder cancer].

Authors:  T Maurer; T Horn; A J Beer; M Eiber; J E Gschwend
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

7.  External validation of existing nomograms predicting lymph node metastases in cystectomized patients.

Authors:  Miroslav M Stojadinovic; Rade I Prelevic
Journal:  Int J Clin Oncol       Date:  2014-04-11       Impact factor: 3.402

8.  Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation.

Authors:  M Gierth; H M Fritsche; H Buchner; M May; A Aziz; W Otto; C Bolenz; L Trojan; E Hermann; A Tiemann; S C Müller; J Ellinger; S Brookman-May; C G Stief; D Tilki; P Nuhn; T Höfner; M Hohenfellner; A Haferkamp; J Roigas; M Zacharias; W F Wieland; H Riedmiller; S Denzinger; P J Bastian; M Burger
Journal:  World J Urol       Date:  2013-06-05       Impact factor: 4.226

9.  Scoring system for prediction of lymph node metastasis in radical cystectomy cohort.

Authors:  Miroslav M Stojadinović; Rade Prelević; Arso Vukićević
Journal:  Int Urol Nephrol       Date:  2014-01-29       Impact factor: 2.370

Review 10.  [Molecular multimodal hybrid imaging in prostate and bladder cancer].

Authors:  T Maurer; M Eiber; B J Krause
Journal:  Urologe A       Date:  2014-04       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.